KOD updated stock price target summary. The average analyst price target of KOD is higher than 94.04% of Pharmaceutical Products stocks. Day low. High volatility in Kodiak Sciences Inc. stock price on Friday which ended trading at $120.49 (Updated on March 05, 2021) Sell candidate since 2021-02-22 Loss -1.73% PDF . Get the hottest stocks to trade every day before the market opens 100% free. Kodiak Sciences Inc's variance in analysts' estimates is less than 7.02% of all US stocks. The Kodiak Sciences Inc. stock price gained 7.90% on the last trading day (Friday, 5th Mar 2021), rising from $111.67 to $120.49.During the day the stock fluctuated 11.19% from a day low at $108.57 to a day high of $120.72. Kodiak Sciences has a consensus rating of “Hold” and a consensus price target of $129.67. The new note on the price target was released on November 13, 2020, representing the official price target for Kodiak Sciences Inc. stock. According to the market data, Kodiak Sciences Inc (KOD) stock price is $131.44 and the 52 weeks low is $35.49, which means the Kodiak Sciences Inc stock price is up 125.53% in the last 12 months. 07:57 AM ET. Click here now. The stock traded as high as $160.18 and last traded at $158.84. 04:23 PM ET. The latest price target for . Profitability This table compares Kodiak Sciences and Fusion … Kodiak Sciences shares closed at $145.58 on Tuesday. ET by Tomi Kilgore Kodiak Sciences downgraded to neutral from overweight at J.P. Morgan Kodiak Sciences stock price target raised to $125 from $74 at J.P. Morgan MarketWatch. Kodiak Sciences Inc. analyst ratings, historical stock prices, earnings estimates & actuals. KOD has a greater upside potential (average analyst target price relative to current price) than 8.79% of Pharmaceutical Products stocks. Stock: KOD, Company: Kodiak Sciences Inc. Avg Volume (4 weeks): 333,047: 4 Weeks Range: 108.10 - 171.21: 4 Weeks Price Volatility (%): *The average price target includes all analyst analysis, not just the most recent analysis presented in the chart. Previously, the target price had yet another raise to $74, while BMO Capital Markets analysts kept a Outperform rating on KOD stock. This price target is based on 14 analysts offering 12 month price targets for Kodiak Sciences in the last 3 months. MT Newswires. 52 week low. Analyst Actions: UBS Starts Kodiak Sciences at Buy With $170 Price Target. Analyst Actions: Berenberg Starts Kodiak Sciences at Buy With $156 Price Target. The current consensus among 5 TipRanks analysts is for a Strong Buy rating of shares in Kodiak Sciences, with an average price target of $75. The company’s average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings. They issued a buy rating and a $170.00 price target on the stock. 12/17 10:23. We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, analyst recommendations, earnings and institutional ownership. Chardan Capital analyst Gbola Amusa reiterated a Buy rating on Kodiak Sciences (KOD – Research Report) today and set a price target of $40.00.The company’s shares closed last Monday at $23.30, close to its 52-week high of $24.25. $120.38. Kodiak Announces 1-Year Durability, Efficacy and Safety Data from Ongoing Phase 1b Study of KSI-301 in Patients with Wet AMD, DME and RVO at Angiogenesis 2021; Kodiak Sciences Announces Closing of $645.0 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares in a research note on Friday, November 13th. Kodiak Sciences Inc. (NASDAQ:KOD) concluded the trading at $120.49 on Friday, Mar 05, with a rise of 7.9% from its closing price on previous day. Kodiak Sciences, a clinical stage biopharmaceutical company, provides novel therapeutics to treat retinal diseases. --Analyst Actions: BMO Capital Adjusts Kodiak Sciences' Price Target to $138 From $148, Maintains Market Perform Rating 11:00AM ET 3/02/2021 MT Newswires (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. UBS Group started coverage on shares of Kodiak Sciences in a research note on Tuesday, December 15th. $35.49 $171.21 Call Option for Kodiak Sciences Inc. At the close of trading, the stock’s price was $126.31, to imply a decline of -1.53% or -$1.96 in intraday trading. The stock had previously closed at $149.93. Kodiak Sciences (KOD) Q3 Earnings Miss, KSI-301 in Focus. Several brokerages have […] According to TipRanks.com, Amusa is a 5-star analyst with an average return of 18.1% and a 50.0% success rate. Kodiak Sciences (NASDAQ:KOD) and Fusion Pharmaceuticals (NASDAQ:FUSN) are both medical companies, but which is the superior investment? Kodiak Sciences Inc has an analyst consensus of Moderate Buy, with a price target consensus of $22.50. Kodiak Sciences (NASDAQ: KOD) was reported by Berenberg on 2020-12-17. UBS Group initiated coverage on shares of Kodiak Sciences in a research report on Tuesday, December 15th. Kodiak Sciences does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Tuesday, March 24, 2020. The average price target represents a -18.18% upside from the last price of $149.01. Analyst Opinions for Kodiak Sciences Inc Registered Shs All Kodiak Sciences Stock Forecast, KOD stock price prediction. The average price target is $121.92, with a high forecast of $170.00 and a low forecast of $69.00. The company's lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biological agent that is in Phase 1b clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy. According to analysts’ consensus price target of $84.70, Kodiak Sciences has a forecasted downside of 25.2% from its current price of $113.17. The Goldman Sachs Group downgraded shares of Kodiak Sciences to a neutral rating and set a $105.00 price target on the stock. Analyst Actions: Citigroup Starts Kodiak Sciences at Neutral With $134 Price Target. Roth Capital cut shares of Kodiak Sciences from a “buy” rating to a “neutral” rating and increased their target price for the company from $133.00 to $155.00 in a research report on Wednesday, February 17th. 52 week high. Kodiak Sciences downgraded to neutral from overweight at J.P. Morgan MarketWatch. Morgan Stanley raised the price target on Roku Inc (NASDAQ: ROKU ) from $200 to $275. At the close of trading, the stock’s price was $131.44, to imply a decline of -1.98% or -$2.66 in intraday trading. Biotech stocks have held up better than the broader market — and these five are potential winners MarketWatch. See today’s analyst top recommended stocks >> Based on Kodiak Sciences Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $11.39 million. 3/8/2021 – Kodiak Sciences had its price target raised by […] In recent trading, shares of Kodiak Sciences Inc (Symbol: KOD) have crossed above the average analyst 12-month target price of $83.56, changing hands for $84.81/share. When a … Approximately 204,370 shares traded hands during mid-day trading, a decline of 28% from the average daily volume of 282,111 shares. Roth Capital lowered shares of Kodiak Sciences (NASDAQ:KOD) from a buy rating to a neutral rating in a report released on Wednesday, Analyst Price Targets reports. 12/16 08:04. Kodiak Sciences (KOD) reports wider-than-expected loss in the third quarter of 2020. Day high. Other analysts have also recently issued reports about the stock. Kodiak Sciences Inc. (NASDAQ:KOD)’s traded shares stood at 361,287 during the last session, with the company’s beta value hitting 0. The company is progressing well with the development of its lead pipeline candidate KSI-301. A number of research firms have changed their ratings and price targets for Kodiak Sciences (NASDAQ: KOD): 3/8/2021 – Kodiak Sciences had its “underweight” rating reaffirmed by analysts at Barclays PLC. Shares of Kodiak Sciences Inc. (NASDAQ:KOD) rose 5.9% during trading on Monday . Roth Capital currently has $155.00 price target on the stock, up from their prior price target of $133.00. They now have a $90.00 price target on the stock, up previously from $52.00. Kodiak Sciences Inc. (NASDAQ:KOD)’s traded shares stood at 496,750 during the last session, with the company’s beta value hitting 0. Earnings-wise, Kodiak Sciences is expected to earn $2.19 per share for the current quarter, ... Bulls will target $85. Roku shares fell 1% to $465.00 in pre-market trading. Find real-time KOD - Kodiak Sciences Inc stock quotes, company profile, news and forecasts from CNN Business. BMO Capital analyst Matthew Luchini lowered the price target on Kodiak Sciences Inc. (NASDAQ: KOD) to $138.00 (from $148.00) while maintaining a … Kodiak Sciences has received a consensus rating of Buy. Kodiak Sciences stock price target raised to $125 from $74 at J.P. Morgan Nov. 30, 2020 at 7:57 a.m. MT Newswires. Kodiak’s drug candidates are investigational compounds in development and have not received regulatory approval in any country. $133.34.
Le Voltaire In Omaha, Pokémon Platinum Route 228 Cave, Roman Symbol For Brotherhood, Oregon Eitc Notice 2020, Uk Visit Visa From Pakistan 2020, Baby Sprinkle Party, Bulk Refuse Guernsey, Melton Council Pay Rate, Fourth Plinth 2020, Columbia Music Major,